NeoGenomics Will Participate in Upcoming Multiple Institutional Investor Conferences

FT. Myers, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), A leading provider of cancer-focused genetic testing and global oncology contract research services, today announced that senior management will participate in several upcoming institutional investor conferences.

  • Management will participate in investor meetings and a presentation at the 42nd Annual William Blair Growth Stocks Conference in Chicago, Wednesday, June 8, 2022. The presentation is scheduled for 12:20 PM ET and will be broadcast live.

  • Management will participate in investor meetings at the 43rd annual Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, California, on Monday, June 13, 2022.

The live online broadcast will be accessed online through the Investors section of the Company’s website, www.neogenomics.com.

About NeoGenomics, Inc.
NeoGenomics, Inc. Specializing in cancer genetics testing and information services, offering one of the world’s most comprehensive oncology-focused testing lists to clinicians to help them diagnose and treat cancer. The company’s pharmaceutical services division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life-changing treatments and experiences. We believe that, with our partners, we can help cancer patients today and the next person diagnosed tomorrow. In carrying out these obligations, NeoGenomics complies with all relevant data protection laws, and provides transparency and choice to patients regarding the handling and use of their data through our Site. Notice of Privacy Practicesand invested in leading-edge technologies to ensure the data we hold is secure at all times.

About NeoGenomics, Inc.
NeoGenomics, Inc. Specializing in cancer genetics testing and information services, offering one of the world’s most comprehensive oncology-focused testing lists to clinicians to help them diagnose and treat cancer. The company’s pharmaceutical services division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life-changing treatments and experiences. We believe that, with our partners, we can help cancer patients today and the next person diagnosed tomorrow. In carrying out these obligations, NeoGenomics complies with all relevant data protection laws, and provides transparency and choice to patients regarding the handling and use of their data through our Site. Notice of Privacy Practicesand invested in leading-edge technologies to ensure the data we hold is secure at all times.

NeoGenomics is headquartered in Fort Myers, Florida and operates CAP-certified and CLIA-accredited laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad, San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Phoenix, Arizona; and CAP accredited laboratories in Cambridge, UK; Rolle, Switzerland; Singapore and China. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical companies, integrated service delivery networks, managed care organizations throughout the United States, and pharmaceutical companies in Europe and Asia.

forward-looking statements

This press release contains forward-looking statements. These forward-looking statements may generally be identified by the use of words such as “expect,” “expect,” “plan,” “could,” “will,” “may,” “will,” “believe,” “estimate,” “predict,” “target,” and “Project,” “direction,” “plan,” “potential” and other words with a similar meaning, although not all forward-looking statements contain these words. These forward-looking statements address various matters, including statements relating to improving operational efficiency, and a return to profitable growth and an ongoing executive hiring process.Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied.Such a statement includes applicable risks and uncertainties, from Among other things, the company’s ability to identify and implement appropriate financial and operational initiatives to improve performance, identify and appoint executive candidates, to continue generating new customer gains, respond to the impacts of the COVID-19 outbreak, introduce new types of testing, consolidate acquisitions and implement their business plan, risks specified under the heading The “risk factors” in the company’s annual report on Form 10-K for the year ended December 31, 2021 were filed with the Securities and Exchange Commission on February 25, 2022 in addition to other information previously submitted to the Securities and Exchange Commission.

Investors are cautioned not to place undue reliance on the forward-looking statements contained in this press release. We encourage you to read our filings with the Securities and Exchange Commission, available at www.sec.gov, to discuss these and other risks and uncertainties. The forward-looking statements contained in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any such statements. Our business is subject to significant risks and uncertainties, including those referred to above. Investors, potential investors, and others should carefully consider these risks and uncertainties.

For more information, please contact:

Charlie Edson
Investor Relations and Corporate Development Manager
T: 239.768.0600 x 2726
M: 952.221.8816
charlie.eidson@neogenomics.com

source: NeoGenomics, Inc.

View the source version on accesswire.com:
https://www.accesswire.com/703858/NeoGenomics-To-Participate-In-Multiple-Upcoming-Institutional-Investor-Conferences